A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Four monthly treatments with pegylated liposomal doxorubicin, thalidomide and dexamethasone
for newly diagnosed myeloma patients as induction therapy prior to high dose chemotherapy and
autologous stem cell transplant.
Phase:
Phase 2
Details
Lead Sponsor:
University of Kansas University of Kansas Medical Center